SuperworthAllogene Therapeutics EPS ALLO
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$0.67
- Latest quarter, Q2 FY26
- −$0.13
- Fiscal year 2025
- −$0.87
Allogene Therapeutics' earnings per share was −$0.67 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.13.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.87 | n/a |
| FY2024 | −$1.33 | n/a |
| FY2023 | −$2.11 | n/a |
| FY2022 | −$2.32 | n/a |
| FY2021 | −$1.89 | n/a |
| FY2020 | −$2.08 | n/a |
| FY2019 | −$1.81 | n/a |
| FY2018 | −$55.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.13 | n/a | −$0.67 | |
| Q1 FY26 | −$0.18 | n/a | −$0.77 | |
| Q4 FY25 | −$0.17 | n/a | −$0.87 | |
| Q3 FY25 | −$0.19 | n/a | −$0.98 | |
| Q2 FY25 | −$0.23 | n/a | −$1.11 | |
| Q1 FY25 | −$0.28 | n/a | −$1.23 | |
| Q4 FY24 | −$0.28 | n/a | −$1.33 | |
| Q3 FY24 | −$0.32 | n/a | −$1.56 | |
| Q2 FY24 | −$0.35 | n/a | −$1.61 | |
| Q1 FY24 | −$0.38 | n/a | −$1.80 | |
| Q4 FY23 | −$0.51 | n/a | −$2.11 | |
| Q3 FY23 | −$0.37 | n/a | −$2.26 |
Against its peers
Companies in Biotechnology nearest Allogene Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ALLOAllogene Therapeutics | −$0.67 | |
| MGTXMeiraGTx | $0.71 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Allogene Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.